NDAORALTABLET
Approved
Apr 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
6/8 — Strong
HYZAAR (losartan potassium and hydrochlorothiazide) by Merck & Co. is [formed from angiotensin i in a reaction catalyzed by angiotensin converting enzyme (ace, kininase ii)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. Approved for hypertension, to lower blood pressure, stroke in patients with hypertension and 3 more indications. First approved in 1995.
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYZAAR is a fixed-dose combination of losartan potassium (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) for oral treatment of hypertension. It works by blocking angiotensin II-mediated vasoconstriction and aldosterone secretion while simultaneously promoting sodium and water excretion. The dual mechanism provides enhanced blood pressure reduction compared to monotherapy.
$0.002BPart D
LOE ApproachingDeclining
HYZAAR is approaching loss of exclusivity with minimal Part D spending ($2M in 2023) and declining claims, signaling a mature asset with reduced commercial investment and smaller team requirements.
Mechanism of Action
[formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone…
Pharmacologic Class:
Thiazide Diuretic
Worked on HYZAAR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.